Skip to main content
. Author manuscript; available in PMC: 2014 Jul 8.
Published in final edited form as: J Neurooncol. 2013 Mar 23;113(2):343–344. doi: 10.1007/s11060-013-1113-7
Median survival (months) 2 year survival 3 year survival 4 year survival 5 year survival
Radiation 11.8 5.7 % 2.3 % 2.3 % 0%
Radiation and temozolomide 10.9 21.8 % 12.3 % 8.8 % 6.5 %

From: Stupp et al. Lancet Oncol 2009. Patients over the age of 60